Latest from Incanthera

Resignation of Professor Richard Greene

Incanthera, the drug development and targeted cancer medicines company (“Incanthera” or “the Company”) advises that Professor Richard Greene has resigned from his position on the Board of Incanthera.

Professor Greene has been on the Board since 25th March 2014 and his resignation is effective from 24th March 2016.

Professor Greene leaves his current position as Dean of the Faculty of Life Sciences at the University of Bradford, to take up a position as Pro-Vice-Chancellor for Research and Knowledge Exchange at Manchester Metropolitan University (“MMU”)

Commenting on Professor Greene’s departure, Simon Ward, Chief Executive of Incanthera said:

“Richard is an inspirational, ground breaking leader of research and technology in this country. We have been very fortunate to have benefitted from his wealth of expertise and innovation whilst he has been a Board member. We wish Richard continued success as he commences his new position at Manchester Metropolitan University”

Professor Richard Greene commented:                                                                              
"I have great admiration for the scientists upon whose work Incanthera is founded and for the innovation professionals who are driving it forward. I'm very excited about my new role at MMU but regrettably the move means that I can no longer serve as the University of Bradford’s nominated director on the Board. I will however watch with interest and affection to see how the Company progresses in the coming years."

For further information, please contact:

Tim McCarthy, Chairman 07831 675747

Simon Ward, Chief Executive Officer 07747 625506

Montgomery Communications

Suzanne Brocks 07776 234600

Notes to Editors

Established in 2010, Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.

Operating from Manchester, with research facilities in Bradford and Salford, Incanthera was established from the University of Bradford’s Institute of Cancer Therapeutics ( to develop oncology treatments from a low cost base via a productive pipeline of early stage technology opportunities.

The Company is uniquely positioned to access commercially valuable patent estates and development programmes, initially from the Institute, but with a wider horizon for pipeline acquisition.

Managed by a team of experienced individuals drawn from commercial, scientific and regulatory backgrounds, the team also has experience in the establishment, growth and exit of small to medium sized companies.

The website at has been designed to showcase the Company’s outstanding expertise in cancer therapeutic technologies.